Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion

Francesco Pichi, Claudia Specchia, Lucia Vitale, Andrea Lembo, Mariachiara Morara, Chiara Veronese, Antonio P. Ciardella, Paolo Nucci

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose To test a combination of dexamethasone intravitreal implant with macular grid laser for macular edema in patients with branch retinal vein occlusion (BRVO). Design Prospective interventional, randomized, multicenter study. Methods Patients with macular edema secondary to BRVO underwent an Ozurdex intravitreal implant at baseline. After 1 month, patients were randomly assigned to 2 study groups. Patients in Group 1 were followed up monthly and retreated with Ozurdex implant whenever there was a recurrence of macular edema or a decrease in best-corrected visual acuity (BCVA). In Group 2 patients macular grid laser was performed between weeks 6 and 8. After that, patients were followed up and retreated as for Group 1. Results In Group 1 at 4 months, mean BCVA was 0.49 ± 0.35 logMAR and central retinal thickness (CRT) was 391 ± 172 μm; both improved significantly at 6 months, to 0.32 ± 0.29 logMAR and 322 ± 160 μm, respectively. In Group 2, CRT was reduced significantly to 291 ± 76 μm at 4 months, and BCVA improved to 0.25 ± 0.20 logMAR. At the final visit, BCVA was 0.18 ± 0.14 logMAR and mean CRT was 271 ± 44 μm. The number of Ozurdex implants at 4 months was 12 of 25 (48%) in Group 1 patients vs 3 of 25 (12%) in Group 2 patients (P =.012). At 6 months 3 of 25 patients (12%) in Group 1 vs 0 of 25 (0%) in Group 2 (P =.23) were retreated. Conclusions The combination of Ozurdex implant and macular grid laser is synergistic in increasing BCVA and lengthening the time between injections.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume157
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Retinal Vein Occlusion
Dexamethasone
Lasers
Visual Acuity
Macular Edema
Therapeutics
Multicenter Studies
Recurrence
Injections

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion. / Pichi, Francesco; Specchia, Claudia; Vitale, Lucia; Lembo, Andrea; Morara, Mariachiara; Veronese, Chiara; Ciardella, Antonio P.; Nucci, Paolo.

In: American Journal of Ophthalmology, Vol. 157, No. 3, 03.2014.

Research output: Contribution to journalArticle

Pichi, Francesco ; Specchia, Claudia ; Vitale, Lucia ; Lembo, Andrea ; Morara, Mariachiara ; Veronese, Chiara ; Ciardella, Antonio P. ; Nucci, Paolo. / Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion. In: American Journal of Ophthalmology. 2014 ; Vol. 157, No. 3.
@article{a23bcdf2d74f4a288515be507dff60ff,
title = "Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion",
abstract = "Purpose To test a combination of dexamethasone intravitreal implant with macular grid laser for macular edema in patients with branch retinal vein occlusion (BRVO). Design Prospective interventional, randomized, multicenter study. Methods Patients with macular edema secondary to BRVO underwent an Ozurdex intravitreal implant at baseline. After 1 month, patients were randomly assigned to 2 study groups. Patients in Group 1 were followed up monthly and retreated with Ozurdex implant whenever there was a recurrence of macular edema or a decrease in best-corrected visual acuity (BCVA). In Group 2 patients macular grid laser was performed between weeks 6 and 8. After that, patients were followed up and retreated as for Group 1. Results In Group 1 at 4 months, mean BCVA was 0.49 ± 0.35 logMAR and central retinal thickness (CRT) was 391 ± 172 μm; both improved significantly at 6 months, to 0.32 ± 0.29 logMAR and 322 ± 160 μm, respectively. In Group 2, CRT was reduced significantly to 291 ± 76 μm at 4 months, and BCVA improved to 0.25 ± 0.20 logMAR. At the final visit, BCVA was 0.18 ± 0.14 logMAR and mean CRT was 271 ± 44 μm. The number of Ozurdex implants at 4 months was 12 of 25 (48{\%}) in Group 1 patients vs 3 of 25 (12{\%}) in Group 2 patients (P =.012). At 6 months 3 of 25 patients (12{\%}) in Group 1 vs 0 of 25 (0{\%}) in Group 2 (P =.23) were retreated. Conclusions The combination of Ozurdex implant and macular grid laser is synergistic in increasing BCVA and lengthening the time between injections.",
author = "Francesco Pichi and Claudia Specchia and Lucia Vitale and Andrea Lembo and Mariachiara Morara and Chiara Veronese and Ciardella, {Antonio P.} and Paolo Nucci",
year = "2014",
month = "3",
doi = "10.1016/j.ajo.2013.11.016",
language = "English",
volume = "157",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion

AU - Pichi, Francesco

AU - Specchia, Claudia

AU - Vitale, Lucia

AU - Lembo, Andrea

AU - Morara, Mariachiara

AU - Veronese, Chiara

AU - Ciardella, Antonio P.

AU - Nucci, Paolo

PY - 2014/3

Y1 - 2014/3

N2 - Purpose To test a combination of dexamethasone intravitreal implant with macular grid laser for macular edema in patients with branch retinal vein occlusion (BRVO). Design Prospective interventional, randomized, multicenter study. Methods Patients with macular edema secondary to BRVO underwent an Ozurdex intravitreal implant at baseline. After 1 month, patients were randomly assigned to 2 study groups. Patients in Group 1 were followed up monthly and retreated with Ozurdex implant whenever there was a recurrence of macular edema or a decrease in best-corrected visual acuity (BCVA). In Group 2 patients macular grid laser was performed between weeks 6 and 8. After that, patients were followed up and retreated as for Group 1. Results In Group 1 at 4 months, mean BCVA was 0.49 ± 0.35 logMAR and central retinal thickness (CRT) was 391 ± 172 μm; both improved significantly at 6 months, to 0.32 ± 0.29 logMAR and 322 ± 160 μm, respectively. In Group 2, CRT was reduced significantly to 291 ± 76 μm at 4 months, and BCVA improved to 0.25 ± 0.20 logMAR. At the final visit, BCVA was 0.18 ± 0.14 logMAR and mean CRT was 271 ± 44 μm. The number of Ozurdex implants at 4 months was 12 of 25 (48%) in Group 1 patients vs 3 of 25 (12%) in Group 2 patients (P =.012). At 6 months 3 of 25 patients (12%) in Group 1 vs 0 of 25 (0%) in Group 2 (P =.23) were retreated. Conclusions The combination of Ozurdex implant and macular grid laser is synergistic in increasing BCVA and lengthening the time between injections.

AB - Purpose To test a combination of dexamethasone intravitreal implant with macular grid laser for macular edema in patients with branch retinal vein occlusion (BRVO). Design Prospective interventional, randomized, multicenter study. Methods Patients with macular edema secondary to BRVO underwent an Ozurdex intravitreal implant at baseline. After 1 month, patients were randomly assigned to 2 study groups. Patients in Group 1 were followed up monthly and retreated with Ozurdex implant whenever there was a recurrence of macular edema or a decrease in best-corrected visual acuity (BCVA). In Group 2 patients macular grid laser was performed between weeks 6 and 8. After that, patients were followed up and retreated as for Group 1. Results In Group 1 at 4 months, mean BCVA was 0.49 ± 0.35 logMAR and central retinal thickness (CRT) was 391 ± 172 μm; both improved significantly at 6 months, to 0.32 ± 0.29 logMAR and 322 ± 160 μm, respectively. In Group 2, CRT was reduced significantly to 291 ± 76 μm at 4 months, and BCVA improved to 0.25 ± 0.20 logMAR. At the final visit, BCVA was 0.18 ± 0.14 logMAR and mean CRT was 271 ± 44 μm. The number of Ozurdex implants at 4 months was 12 of 25 (48%) in Group 1 patients vs 3 of 25 (12%) in Group 2 patients (P =.012). At 6 months 3 of 25 patients (12%) in Group 1 vs 0 of 25 (0%) in Group 2 (P =.23) were retreated. Conclusions The combination of Ozurdex implant and macular grid laser is synergistic in increasing BCVA and lengthening the time between injections.

UR - http://www.scopus.com/inward/record.url?scp=84894145896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894145896&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2013.11.016

DO - 10.1016/j.ajo.2013.11.016

M3 - Article

C2 - 24528934

AN - SCOPUS:84894145896

VL - 157

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -